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(SUV) were compared using linear-mixed modeling at baseline and at 
four weeks after RT for target and non-target lesions. 
Results: Eleven patients were eligible for analysis. There were 13 
target lesions (two irradiated target lesions in two patients) and 12 
non-target lesions (treated with sorafenib alone). Two patients 
experienced severe toxicity: one developed hand-foot syndrome and 
another died during treatment from unrelated causes. There were no 
severe side effects directly attributable to the combination of RT and 
sorafenib. The BPI mean ‘present’ pain scores at baseline, 7 weeks 
and 12 weeks were 3.9, 1.6, and 1.6 respectively (p = 0.07 for 7 weeks 
vs. baseline; p = 0.13 for 12 weeks versus baseline). There was a 
significant difference in the metabolic response of target lesions 
versus non-target lesions (p=0.002). For target lesions, SUV decreased 
after RT and sorafenib (p=0.003). However, for non-target lesions, 
there was a trend towards an increase in SUV (p=0.09). Only two 
patients required re-irradiation of a previously treated index lesion. 
Seven other patients required subsequent RT for symptomatic 
progression of previously untreated lesions. 
Conclusions: The combination RT and sorafenib is feasible and well 
tolerated as a treatment for palliation of painful bone metastases in 
patients with metastatic RCC. Both the re-treatment and PET results 
suggest that RT provides additional palliative benefit in this patient 
population and should be considered even in those receiving tyrosine-
kinase inhibitors like sorafenib. 
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Purpose/Objective: End point of the present study is to evaluate the 
technical feasibility and early side effects of a short course 
hypofractionated high dose LINAC based SBRT delivered with 
Flattened Filter Free (FFF) beams, and SpaceOAR as a spacer between 
rectum and prostate. 
Materials and Methods: This is a prospective phase-I-II pilot feasibility 
study, started on February 2012. Inclusion criteria were: age ≤ 80 
years, WHO PS ≤ 2, PSA ≤ 20 ng/ml, histologically proven prostate 
adenocarcinoma(risk of microscopic nodal involvement ≤ 15%), T1-T2 
stage, no distant metastases, no previous prostate surgery other than 
TURP, no malignant tumours in the previous 5 years, IPSS 0-7. The 
schedule was 5 x 7 Gy = 35 Gy, delivered in 5 alternative days (NTD2 
between 70 and 85 Gy for an α/β between 3 and 1.5 Gy, respectively). 
SBRT was delivered using the volumetric modulated arc technique by 
RapidArc, with photon beam energy of 10 MV FFF (Filter Flattening 
Free) and maximum dose rate of 2400 MU/min. Physical examinations 
and toxicity assessments were performed during and after SBRT 
according to CTCAE v4.0 toxicity scale. EPIC questionnaires were used 
for Quality of Life assessing. Tumour response was evaluated on 
ASTRO PHOENIX definition (+2 from Nadir of PSA). Neo-
adjuvant/concomitant hormonal therapy was prescribed based on the 
risk according to NCCN classification. SpaceOAR was implanted by 
intraperineal injection as a spacer to enlarge the minimum distance 
between prostate and anterior rectal wall. The SpaceOAR implant was 
optional and based on clinician decision for each case. 
Results: With a median follow-up of 6 months(1-9),40 patients were 
treated with this schedule and were evaluable for the current 
analysis. 34/40 patients were officially recruited in the protocol and 
met perfectly all inclusion criteria. Other 6/40 'out of trial' were 
treated with the same protocol. In the trial, according to NCCN 
criteria, 21/34 patients were low-risk and 12/34 were Intermediate 
risk. Median Age was 69.6(56-80), median initial PSA was 6.33 
ng/ml(range:0.50-12 ng/ml). Median Gleason score was 6.33(6-7). 
Median treatment duration was 11.8 days(9-22). All patients 
completed the treatment as programmed. Acute Toxicities were as 
follow: Rectum G0 in 21/34 cases(62%), G1 in 11/34(33%); G2 in 
2/34(5%). Genito-urinary G0 in 15/34 cases(45%), G1 in 7/34(20%), G2 
in 12/34(35%). In two G2 urinary retention cases, the placement of 
intermittent catheter was needed(in both cases prostate dimension 
was superior than100cc). No acute G3-5 was found in the trial and 'out 
of trial'patients. Median treatment time was 109 seconds(63-124). 
SpaceOAR was implanted in 9 patients with a single case of rectal 
fascia infection resolved with antibiotics. During Follow-up, PSA 
reduction was documented in all treated patients. 
Conclusions: Our early findings suggest that LINAC based SBRT FFF 
treatment for prostate cancer in 5 fractions is feasible, fast and well 
tolerated in acute setting for the first 40 treated patients. Longer 
follow-up is needed for definitive assessment of late toxicity and 
clinical outcome.  
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Purpose/Objective: To assess urinary (GU) function and toxicity in 
patients treated with image-guided proton therapy (PT) for early- and 
intermediate-risk prostate cancer and to analyze the impact of 
pretreatment urinary obstructive symptoms on urinary function after 
PT. 
Materials and Methods: Two prospective trials accrued 171 prostate 
cancer patients from August 2006 to September 2007. Low-risk 
patients received 78 cobalt gray equivalent (CGE) in 39 fractions and 
intermediate-risk patients received 78 to 82 CGE. Median follow-up 
was 5 years. The International Prostate Symptom Score (IPSS) and GU 
toxicities (per CTCAE v3.0 and v4.0) were documented prospectively. 
Results: Five transient GU events were scored Gr 3 per CTCAE v4.0, 
for a cumulative late GU toxicity rate of 2.9% at 5 years. There were 
no Gr 4 or 5 events. On multivariate analysis (MVA), the only factor 
predictive of Gr 2+ GU toxicity was pretreatment GU symptom 
management (p=0.0058).  
Patients with pretreatment IPSS of 15-25 had a decline (clinical 
improvement) in median IPSS from 18 before treatment to 10 at their 
60-month follow-up. At last follow-up,18 (54.5%) patients had a > 5-
point decline, 14 (42.5%) remained stable, and 2 patients (3%) had a > 
5-point rise (deterioration) in IPSS. Patients with IPSS <15 had a stable 
median IPSS of 6 before treatment and at 60 months.  
Conclusions: Urologic toxicity at 5 years with image-guided PT has 
been uncommon and transient. Patients with pretreatment IPSS of < 
15 had stable urinary function 5 years after PT, but patients with 15-
25 showed substantial improvement (decline) in median IPSS, a finding 
not explained by initiation or dose adjustment of alpha blockers. This 
suggests that PT provides a minimally toxic and effective treatment 
for low and intermediate prostate cancer patients, including those 
with significant pretreatment GU dysfunction (IPSS15-25).  
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Purpose/Objective: Accumulating evidence demonstrates the 
sensitivity of prostate cancer to fractionation, estimating a low α/ß 
ratio. This suggests a significant therapeutic benefit of 
hypofractionation, delivering a higher biological dose to the prostate 
without increasing toxicity. To test this hypothesis a randomized 
multicenter phase III Hypofractionation Trial was performed in The 
Netherland. Here we report on the first results of late toxicity. 
Materials and Methods: Between April 2007 and January 2011, 820 
men with localized prostate cancer were included. They were 
randomly assigned to a standard fractionation (SF) arm of 39x2 Gy (5 
fractions a week), or a hypofractionated (HF) arm of 19x3.4 Gy (3 
fractions a week). Primary endpoints were relapse-free survival (RFS) 
and toxicity scores. The late toxicity scores were measured twice a 
year after finishing the radiation course (RC) using RTOG/EORTC 
criteria. The highest grade scored in the follow-up was considered. 
Analyses were done based on the intention to treat. 
Results: To each fractionation arm 410 patients were randomly 
assigned. The median follow-up was 27 months (range 2.3-57 months). 
A grade ≥ 2 late gastrointestinal toxicity (GI) after finishing the RC 
was reported by 15% of the patients treated with SF and by 20% of the 
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patients treated with HF, respectively (p=0.154). Grade ≥ 2 late 
genitourinary (GU) toxicity was experienced by 41% and 43% of 
patients treated with SF and HF, respectively (p=0.532). 
From 3 months after RC, only 2% of patients experienced a grade 3 
late GI toxicity in the SF arm versus 1% in the HF arm (p=0.337). Grade 
4 late GI toxicity was reported in 1 patient in the SF arm versus 4 
patients in the HF arm (p=0.373). Late GU grade 3 toxicity was 
reported by 9% and 14% in the SF- and HF arm, respectively (p=123). 
No grade 4 late GU toxicity was reported in the SF arm versus 1 
patient in the HF arm. 
A multivariable analysis evaluating the effect of age, PSA, Gleason-
score, T-stage, use of hormonal therapy, previous TURP, smoking and 
the presence of acute GI/GU toxicity showed that only the presence 
of acute toxicity significantly increased the risk of developing late GI 
toxicity (p=0.000) . For the late GU toxicity, the age >70 (p=0.001), 
the presence of acute GU toxicity (p=0.000) and smoking (p=0.046) 
were significant factors increasing the risk of developing late GU 
toxicity.  
Conclusions: Our initial results on late toxicity, after a median follow-
up of 27 months, show that the hypofractionated treatment is well 
tolerated. No significant differences in late GI and GU toxicity were 
observed compared to the standard fractionation arm. The presence 
of acute GI and GU toxicity were significant prognostic factors for late 
toxicity. Age and smoking were significant prognostic factors for late 
GU toxicity as well.  
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Purpose/Objective: Moderate dose escalation and hypofractionation 
(HYPO) have a possible role in the postprostatectomy (POSTOP) 
setting, both adjuvant (ADV) and salvage (SALV). This analysis focused 
on possible clinical and physico-dosimetric predictors of most severe 
(Grade ≥3) genitourinary toxicity (GU TOX) after POSTOP RT for 
prostate cancer (PCa). 
Materials and Methods: A cohort of 1176 consecutive patients (pts) 
was submitted to POSTOP ADV (n=804) or SALV (n=372) RT between 
1993 and 2010 in a single Institution with conventionally fractionated 
(CF, 1.8 Gy/fraction, fr) non conformal (NC, n=169), 3DCRT (n=657) or 
IMRT (n=103) technique, or moderately HYPO (median 2.50 Gy/fr) 
helical Tomotherapy (n=247). The whole-pelvis (WP) was irradiated in 
345 pts. The median dose to the prostatic bed and WP was 70.2 Gy 
and 50.4 Gy, respectively, in the CF group. For the HYPO group, 3 
cohorts were identified: 116 treated at a median of 65.8 Gy (2.35 Gy x 
28), 76 at 71.4 Gy (2.5-2.6 x 28) and 49 at 58 Gy in 20 Gy. In the HYPO 
group the most common WPRT schedule was 51.8 Gy/28 fr. Total 
doses were also converted in biological equivalent doses (BED) 
following the linear quadratic model (LQ) taking a/b = 3 or 5. We 
focused on Grade ≥3 toxicity, retrospectively graded according to 
CTCAE v 4.0. 
Results: After a median follow-up of 95 months (60 for HYPO), 121 pts 
experienced Grade 3 late TOX (57 urethral or bladder neck strictures 
requiring interventions ± 49 severe urinary incontinence 
onset/worsened after RT ± 25 gross haematuria) and 5 underwent 
cystectomy (Grade 4). Patients were grouped in 3 classes, according 
to the dose/fr received: A=1.8-2.0 Gy, B=2.3-2.4 Gy, C=2.5-2.9 Gy. At 
univariate analysis, the 5-year risk of TOX G≥3 was predicted by 
fractionation (7% vs 15% vs 21% for groups A, B and C, respectively, 
p<0.0001), acute Grade ≥2 TOX (18% vs 8%, p=0.0001) and use of anti-
hypertensives (HYPERT, 12% vs 7%, p=0.04). At multivariate analysis 
(MVA) the only predictive covariate of Grade≥3 TOX in the overall 
population was acute Grade ≥2 TOX (HR 2.49, p=0.0002), while 
fractionation (p=0.06) and HYPERT (p=0.09) were found to be of only 
borderline significance. In the HYPO subgroup, the only significant 
variable at MVA was HYPERT (HR 8.15, p=0.008). Overall, BED was not 
predictive. 
Conclusions: This is the largest data set focusing on the impact of 
different doses and fractionations on severe GU toxicity after POSTOP 
RT for PCa, suggesting the existence of an important 'consequential' 
component for the onset of severe late GU toxicity, and an important 
role of HYPERT. Moreover, the impact of an increased daily dose 
effect (from 1.8-2 to 2.3-2.9 Gy/fr) is completely inconsistent with 
the linear-quadratic model, suggesting that HYPO exacerbates severe 
GU TOX far more than would be expected from BED calculation. This 
effect may suggest an increased incomplete repair effect of the 
urothelium, possibly enhanced by the previous surgery. 
 JOINT SYMPOSIUM: ESTRO-CARO: MANAGEMENT OF 
LUNG OLIGO-METASTATIC DISEASE  
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Based on prospective trials, stereotacticbody radiotherapy (SBRT) has 
become the standard of care for early stage non-small cell lung cancer 
(NSCLC): high accuracy of the whole radiotherapy work-flow allowed 
safe delivery of escalated irradiation doses, which significantly 
improved local tumor control and overall survival compared to 
conventionally fractionated radiotherapy. Local surgical treatment of 
oligo-metastatic lung and / or liver lesions has shown promising long 
term overall survival with cure in a proportion of the patients and 
these results were the rational for exploring the role of SBRT in the 
setting of pulmonary metastases. Until today, several prospective 
trials have investigated safety and efficacy of SBRT in this metastatic 
setting. The majority of the studies limited the number of treated 
pulmonary lesions or lesions anywhere in the body to 3 – 5 and SBRT 
irradiation doses were similar to experiences in SBRT for stage I 
NSCLC, mostly higher than 100Gy BED. However, lesions were rather 
small in the majority of the studies and risk-adapted fractionation 
with larger number of treatment fractions and lower total doses are 
recommended in the situation of multiple large-volume disease. 
Integration of SBRT into systemic chemotherapy is still poorly 
investigated but the majority of the studies did not allow 
simultaneous chemotherapy and recommended a chemotherapy-free 
interval of several weeks prior to and after SBRT. Clinical outcome of 
SBRT for pulmonary metastases is promising with toxicity grade >2 of 
<10%: radiation induced pneumonitis and chest wall pain were the 
most frequently observed toxicities. Local tumor control was 
consistently achieved in 80-90% of the patients. Despite the majority 
of the patients developed progressive systemic disease, long term 
overall survival was observed in a similar proportion of the patients as 
in the surgical series. Despite these promising results, a better 
understanding of how to select patients, which benefit most from this 
local treatment, is warranted. Additionally, the combination of SBRT 
with concurrent chemotherapy and targeted therapy is poorly 
investigated. Finally, endpoints other than overall survival like 
prolonging a chemotherapy-free interval with improved quality-of-live 
are worth to evaluate in future prospective trials. 
 
SP-0055   
Surgery in pulmonary oligometastases 
P. Granone1 
1Università Cattolica del Sacro Cuore, Surgery, Rome, Italy  
 
Resection of pulmonary metastases is commonly performed in patients 
whose primary disease is controlled. Lung metastases from a primary 
extra pulmonary malignancy are often a manifestation of widespread 
dissemination; however, some patients have no other evidence of 
disease. The largest number of solitary metastases survivors had 
metastases primarily in the lung and/or liver. With innovations in 
molecular imaging and advances in molecular oncology, the stage is 
set to detect truly solitary metastases early.Then, aggressive 
treatment by surgical excision, stereotactic body radiosurgery, 
targeted chemotherapy, or immunotherapy could eradicate the lesion. 
A broader staging system is recommended to encompass a solitary 
metastasis(M1) and oligometastases (M2) as distinct from multiple 
metastases (M3). Even if nonresectional therapies such as radio 
frequency ablation and stereotactic body radiation therapy are being 
used in centers for patients with oligometastases to the lungs,  
extensive experience with pulmonary metastasectomy in a number of 
different cancers has confirmed that resection can substantially 
prolong survival and cure some patients. Based upon these 
observations, aggressive resection of isolated pulmonary metastases 
has become a widely accepted treatment for appropriately selected 
patients. In addition, technological improvements in radiological 
screening of pulmonary metastases and thoracoscopic resection are 
fundamentally altering the management of these patients and their 
surgery. Despite high resolution computed tomography scan and 
positron emission tomography-computed tomography remain the 
preferred imaging modalities for pulmonary metastases, the 
sensitivity of the technique is 100% for lesions larger than 1 cm, but it 
decreases according to the size of the metastases (<5 mm). Indeed, 
there is a real problem of missing small metastatic lesions in the 
video-assisted thoracic surgery approach; complete manual 
